Breast cancer is stratified into luminal, human epidermal receptor 2 (HER2)-enriched, and triple-negative breast cancer (TNBC) subtypes, according to the presence of distinct molecular markers, including the estrogen receptor (ER), progesterone receptor (PR), and HER2 [2]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.